Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapy for Ovarian Cancer in the Older Adult

  • Geriatric Oncology
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

The treatment of epithelial ovarian cancer in the older adult presents many challenges. The standard of care is cytoreductive surgery with the aim of achieving minimal residual disease. Surgery is then usually followed by six cycles of platinum–taxane chemotherapy. Older patients often have comorbidities which limit treatment choice and increase the risk of major surgical procedures. Platinum-based chemotherapy is generally well tolerated in fit elderly patients but can result in more toxicity in patients of increasing age. Results of a recent randomized trial of neoadjuvant platinum-based chemotherapy vs upfront surgery reveal decreased toxicity and equivalent survival in patients who receive chemotherapy prior to surgery. Treatment strategies to reduce the toxicity of chemotherapy include the use of single agent carboplatin, dose reduction, and weekly scheduling. Comprehensive geriatric assessment (CGA) of older patients prior to treatment may predict for toxicity of therapy and even survival. While comprehensive assessment may be desirable, it is impractical in the clinic. A simplified screening tool to detect geriatric problems and the further need for a formal assessment is more feasible. Prospective clinical trials of therapy in the elderly patient population are needed to guide treatment decisions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Morgan R, Alvarez R, Armstrong DK, et al.: NCCN Clinical Practice Guidelines in Oncology—Ovarian Cancer v1.2008. 2008. http://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf

  2. Bristow RE, Tomacruz RS, Armstrong DK, et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248-59. doi:10.1200/JCO.20.5.1248

    Article  PubMed  Google Scholar 

  3. Krivak TC, Darcy KM, Tian C, et al. (2008) Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol 26:3598-606. doi:10.1200/JCO.2008.16.1323

    Article  CAS  PubMed  Google Scholar 

  4. Walsh CS, Ogawa S, Karahashi H, et al. (2008) ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol 26:2952-8. doi:10.1200/JCO.2007.13.5806

    Article  CAS  PubMed  Google Scholar 

  5. Chan JK, Urban R, Cheung MK, et al. (2006) Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer 95:1314-20. doi:10.1038/sj.bjc.6603457

    Article  CAS  PubMed  Google Scholar 

  6. Efstathiou E, Dimopoulos MA, Bozas G, et al.: Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome. Anticancer Res 27:611-7, 2007

    PubMed  Google Scholar 

  7. Hershman D, Jacobson JS, McBride R, et al. (2004) Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol 94:540-9. doi:10.1016/j.ygyno.2004.04.022

    Article  CAS  PubMed  Google Scholar 

  8. Hightower RD, Nguyen HN, Averette HE, et al. (1994) National survey of ovarian carcinoma. IV: Patterns of care and related survival for older patients. Cancer 73:377-83. doi:10.1002/1097-0142(19940115)73:2<377::AID-CNCR2820730223>3.0.CO;2-#

    Article  CAS  PubMed  Google Scholar 

  9. Petignat P, Fioretta G, Verkooijen HM, et al. (2004) Poorer survival of elderly patients with ovarian cancer: a population-based study. Surg Oncol 13:181-6. doi:10.1016/j.suronc.2004.08.010

    Article  CAS  PubMed  Google Scholar 

  10. Winter WE, 3rd, Maxwell GL, Tian C, et al. (2007) Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:3621-7. doi:10.1200/JCO.2006.10.2517

    Article  PubMed  Google Scholar 

  11. Chan JK, Loizzi V, Lin YG, et al. (2003) Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? Obstet Gynecol 102:156-61. doi:10.1016/S0029-7844(03)00399-5

    Article  PubMed  Google Scholar 

  12. Pectasides D, Fountzilas G, Aravantinos G, et al.: Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience. Int J Gynecol Cancer 17:1003-10, 2007

    CAS  PubMed  Google Scholar 

  13. Maas HA, Kruitwagen RF, Lemmens VE, et al. (2005) The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol 97:104-9. doi:10.1016/j.ygyno.2004.12.026

    Article  CAS  PubMed  Google Scholar 

  14. Earle CC, Schrag D, Neville BA, et al.: Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 98:172-80, 2006

    PubMed  Google Scholar 

  15. Sundararajan V, Hershman D, Grann VR, et al. (2002) Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol 20:173-8. doi:10.1200/JCO.20.1.173

    Article  PubMed  Google Scholar 

  16. Bruchim I, Altaras M, Fishman A (2002) Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer. Gynecol Oncol 86:274-8. doi:10.1006/gyno.2002.6759

    Article  PubMed  Google Scholar 

  17. Uyar D, Frasure HE, Markman M, et al. (2005) Treatment patterns by decade of life in elderly women (> or = 70 years of age) with ovarian cancer. Gynecol Oncol 98:403-8. doi:10.1016/j.ygyno.2005.04.037

    Article  PubMed  Google Scholar 

  18. Balducci L: Management of cancer in the elderly. Oncology (Williston Park) 2006, 20:135–143; discussion 144, 146, 151–152

  19. Balducci L: NCCN Clinical Practice Guidelines in Oncology—Senior Adult Oncology. NCCN Publications; 2007

  20. Bouchardy C, Rapiti E, Blagojevic S, et al. (2007) Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol 25:1858-69. doi:10.1200/JCO.2006.10.4208

    Article  PubMed  Google Scholar 

A comprehensive review of the effects of undertreatment in elderly female patients with breast and gynecological malignancies.

  1. Janda M, Youlden DR, Baade PD, et al. (2008) Elderly patients with stage III or IV ovarian cancer: should they receive standard care? Int J Gynecol Cancer 18:896-907. doi:10.1111/j.1525-1438.2007.01122.x

    Article  CAS  PubMed  Google Scholar 

A large population based study of the influence of comorbidity on outcome in elderly patients with advanced ovarian cancer. Comorbidity risk score to predict toxicity requires prospective validation.

  1. Tetsche MS, Dethlefsen C, Pedersen L, et al. (2008) The impact of comorbidity and stage on ovarian cancer mortality: a nationwide Danish cohort study. BMC Cancer 8:31. doi:10.1186/1471-2407-8-31

    Article  PubMed  Google Scholar 

  2. Charlson ME, Pompei P, Ales KL, et al. (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-83. doi:10.1016/0021-9681(87)90171-8

    Article  CAS  PubMed  Google Scholar 

  3. Gronlund B, Hogdall C, Hansen HH, et al. (2002) Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer 94:1961-7. doi:10.1002/cncr.10385

    Article  CAS  PubMed  Google Scholar 

  4. Hershman D, Fleischauer AT, Jacobson JS, et al. (2004) Patterns and outcomes of chemotherapy for elderly patients with stage II ovarian cancer: a population-based study. Gynecol Oncol 92:293-9. doi:10.1016/j.ygyno.2003.10.006

    Article  CAS  PubMed  Google Scholar 

  5. Kyrgiou M, Salanti G, Pavlidis N, et al.: Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst 98:1655-63, 2006

    Article  CAS  PubMed  Google Scholar 

  6. Eisenhauer EL, Tew WP, Levine DA, et al. (2007) Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol 106:381-7. doi:10.1016/j.ygyno.2007.04.012

    Article  CAS  PubMed  Google Scholar 

  7. Pignata S, Monfardini S (2000) Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian carcinoma. Eur J Cancer 36:817-20. doi:10.1016/S0959-8049(00)00050-2

    Article  CAS  PubMed  Google Scholar 

  8. International Collaborative Ovarian Neoplasm Group (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360:505-15. doi:10.1016/S0140-6736(02)09738-6

    Article  Google Scholar 

  9. Fader AN, von Gruenigen V, Gibbons H, et al. (2008) Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol 109:33-8. doi:10.1016/j.ygyno.2008.01.001

    Article  CAS  PubMed  Google Scholar 

  10. Pignata S, Breda E, Scambia G, et al. (2008) A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer* A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol 66:229-36. doi:10.1016/j.critrevonc.2007.12.005

    Article  PubMed  Google Scholar 

  11. Lichtman SM, Hollis D, Miller AA, et al. (2006) Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol 24:1846-51. doi:10.1200/JCO.2005.03.9289

    Article  CAS  PubMed  Google Scholar 

  12. Sehouli J, Stengel D, Mustea A, et al. (2008) Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO. Cancer Chemother Pharmacol 61:243-50. doi:10.1007/s00280-007-0466-z

    Article  CAS  PubMed  Google Scholar 

  13. Isonishi S, Yasuda M, Takahashi F, et al. (2008) Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology. J Clin Oncol 26: 294 s

    Google Scholar 

  14. Ceccaroni M, D’Agostino G, Ferrandina G, et al. (2002) Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study. Gynecol Oncol 85:445-50. doi:10.1006/gyno.2002.6631

    Article  CAS  PubMed  Google Scholar 

  15. Villella JA, Chaudhry T, Pearl ML, et al. (2002) Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancer. Gynecol Oncol 86:316-22. doi:10.1006/gyno.2002.6781

    Article  CAS  PubMed  Google Scholar 

  16. Lichtman SM, Wildiers H, Chatelut E, et al. (2007) International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients–an analysis of the medical literature. J Clin Oncol 25:1832-43. doi:10.1200/JCO.2007.10.6583

    Article  CAS  PubMed  Google Scholar 

  17. Lichtman SM, Wildiers H, Launay-Vacher V, et al. (2007) International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 43:14-34. doi:10.1016/j.ejca.2006.11.004

    Article  PubMed  Google Scholar 

  18. Calvert AH, Newell DR, Gumbrell LA, et al.: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-56, 1989

    CAS  PubMed  Google Scholar 

  19. Chatelut E, Canal P, Brunner V, et al. (1995) Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87:573-80. doi:10.1093/jnci/87.8.573

    Article  CAS  PubMed  Google Scholar 

  20. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. doi:10.1159/000180580

    Article  CAS  PubMed  Google Scholar 

  21. Jelliffe RW: Letter: Creatinine clearance: bedside estimate. Ann Intern Med 79:604-5, 1973

    CAS  PubMed  Google Scholar 

  22. Wright JG, Boddy AV, Highley M, et al. (2001) Estimation of glomerular filtration rate in cancer patients. Br J Cancer 84:452-9. doi:10.1054/bjoc.2000.1643

    Article  CAS  PubMed  Google Scholar 

  23. Marx GM, Blake GM, Galani E, et al. (2004)Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 15:291-5. doi:10.1093/annonc/mdh079

    Article  CAS  PubMed  Google Scholar 

  24. Armstrong DK, Bundy B, Wenzel L, et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43. doi:10.1056/NEJMoa052985

    Article  CAS  PubMed  Google Scholar 

  25. Fujiwara K, Markman M, Morgan M, et al. (2005) Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol Oncol 97:10-5. doi:10.1016/j.ygyno.2004.12.005

    Article  CAS  PubMed  Google Scholar 

  26. Frei E, 3rd (1982) Clinical cancer research: an embattled species. Cancer 50:1979-92. doi:10.1002/1097-0142(19821115)50:10<1979::AID-CNCR2820501002>3.0.CO;2-D

    Article  PubMed  Google Scholar 

  27. Morrison J, Swanton A, Collins S, et al.: Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev 2007, CD005343

  28. Liu EL, Mi RR (2004) Neoadjuvant intraarterial chemotherapy and embolization in treatment of advanced ovarian epithelial carcinoma. Chin Med J (Engl) 117:1547-51

    CAS  Google Scholar 

  29. Vergote I, Tropé C, Amant F, et al.: EORTC-GCG/NCIC-CTG randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIc-IV ovarian, fallopian tube and peritoneal cancer (OVCA), IGCS-12. Bangkok, October 25–28, 2008, Int J Gynecol Cancer 2008

  30. Cloven NG, Manetta A, Berman ML, et al. (1999) Management of ovarian cancer in patients older than 80 years of Age. Gynecol Oncol 73:137-9. doi:10.1006/gyno.1998.5337

    Article  CAS  PubMed  Google Scholar 

  31. Moore KN, Reid MS, Fong DN, et al. (2008) Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol Oncol 110:133-9. doi:10.1016/j.ygyno.2008.03.008

    Article  PubMed  Google Scholar 

  32. Parmar MK, Ledermann JA, Colombo N, et al. (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099-106. doi:10.1016/S0140-6736(03)13718-X

    Article  CAS  PubMed  Google Scholar 

  33. Pfisterer J, Plante M, Vergote I, et al. (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699-707. doi:10.1200/JCO.2006.06.0913

    Article  CAS  PubMed  Google Scholar 

  34. Gordon AN, Fleagle JT, Guthrie D, et al.: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312-22, 2001

    CAS  PubMed  Google Scholar 

  35. Morris R, Alvarez RD, Andrews S, et al. (2008) Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers. Gynecol Oncol 109:346-52. doi:10.1016/j.ygyno.2008.02.028

    Article  CAS  PubMed  Google Scholar 

  36. Mutch DG, Orlando M, Goss T, et al. (2007) Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811-8. doi:10.1200/JCO.2006.09.6735

    Article  CAS  PubMed  Google Scholar 

  37. Markman M, Hall J, Spitz D, et al. (2002) Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 20:2365-9. doi:10.1200/JCO.2002.09.130

    Article  CAS  PubMed  Google Scholar 

  38. Rose PG, Blessing JA, Mayer AR, et al.: Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 16:405-10, 1998

    CAS  PubMed  Google Scholar 

  39. Nicoletto MO, Donach M, Borgato L, et al.: Lack of cardiotoxicity with liposomal doxorubicin in an elderly case of ovarian cancer. Tumori 93:204-6, 2007

    PubMed  Google Scholar 

  40. Uyar D, Kulp B, Peterson G, et al. (2004) Cardiac safety profile of prolonged (> or = 6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies. Gynecol Oncol 94:147-51. doi:10.1016/j.ygyno.2004.03.024

    Article  CAS  PubMed  Google Scholar 

  41. Yildirim Y, Gultekin E, Avci ME, et al. (2008) Cardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m2 in patients with recurrent ovarian and peritoneal cancer. Int J Gynecol Cancer 18:223-7. doi:10.1111/j.1525-1438.2007.00992.x

    Article  CAS  PubMed  Google Scholar 

  42. O’Brien ME, Wigler N, Inbar M, et al. (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440-9. doi:10.1093/annonc/mdh097

    Article  PubMed  Google Scholar 

  43. Saliba D, Elliott M, Rubenstein LZ, et al. (2001) The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 49:1691-9. doi:10.1046/j.1532-5415.2001.49281.x

    Article  CAS  PubMed  Google Scholar 

  44. Freyer G, Geay JF, Touzet S, et al. (2005) Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 16:1795-800. doi:10.1093/annonc/mdi368

    Article  CAS  PubMed  Google Scholar 

  45. Hoff PM (2006) Bevacizumab in older patients and patients with poorer performance status. Semin Oncol 33:S19-25. doi:10.1053/j.seminoncol.2006.08.006

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Border Medical Oncology, Suite 1, 69 Nordsvan Drive, Wodonga, VIC, 3690, Australia

    Christopher B. Steer MBBS, FRACP

Authors
  1. Christopher B. Steer MBBS, FRACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher B. Steer MBBS, FRACP.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steer, C.B. Chemotherapy for Ovarian Cancer in the Older Adult. Curr. Treat. Options in Oncol. 10, 159–170 (2009). https://doi.org/10.1007/s11864-009-0093-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-009-0093-5

Search

Navigation